S&P 5007,675.92▼0.4% Nasdaq26,749.30▼0.7% Dow51,245.74▼0.5% Russell 2K2,826.40▼0.4% 10-Yr5.12%+1bp VIX15.69+0.51 WTI$95.27▲3.4% Gold$4,292.50▼0.6% EUR/USD1.138▼0.6% BTC$83,940▼0.5% Nikkei65,514▲0.8%
At close · Thu, Sep 24, 2026
Daily Market Updates.

Earnings

Home›Earnings›Guidance›Novo Nordisk signs licensing deal worth more than $1 b…

Novo Nordisk signs licensing deal worth more than $1 billion

The deal comes just days after a capital-markets day left investors questioning the company’s next steps.

Reported · Written up by our desk · Guidance

MarketWatch reports that Novo Nordisk, the Danish drugmaker, struck a licensing deal valued at more than $1 billion.

The announcement followed a capital-markets day that left investors unsure about what’s next for the company, according to MarketWatch.

← Newer storyKelpDAO sues LayerZero over rsETH exploit it says was endorsed

More like this

EarningsCintas lifts guidance after posting 10.9% revenue growth
EarningsNew Era Energy & Digital signs 20-year power deal for Texas AI data center
EarningsNike set for Q1 report as Wall Street weighs margins against weak demand
EarningsMillerKnoll lowers full-year sales outlook as demand softens
EarningsMiniMed raises full-year organic revenue outlook to about 10.5%

Sources

MarketWatchAfter capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
MarketWatchAfter capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.